Laurence Reid - Net Worth and Insider Trading

Laurence Reid Net Worth

The estimated net worth of Laurence Reid is at least $2 Million dollars as of 2024-11-05. Laurence Reid is the SVP, Chief Business Officer of Alnylam Pharmaceuticals Inc and owns about 5,671 shares of Alnylam Pharmaceuticals Inc (ALNY) stock worth over $2 Million. Laurence Reid is also the President and Chief Executive of Decibel Therapeutics Inc and owns about 25,849 shares of Decibel Therapeutics Inc (DBTX) stock worth over $126,919. Details can be seen in Laurence Reid's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Laurence Reid has not made any transactions after 2021-09-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Laurence Reid

To

Laurence Reid Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Laurence Reid owns 2 companies in total, including Alnylam Pharmaceuticals Inc (ALNY) , and Decibel Therapeutics Inc (DBTX) .

Click here to see the complete history of Laurence Reid’s form 4 insider trades.

Insider Ownership Summary of Laurence Reid

Ticker Comapny Transaction Date Type of Owner
ALNY Alnylam Pharmaceuticals Inc 2014-11-18 SVP & Chief Business Officer
DBTX Decibel Therapeutics Inc 2021-09-15 director & See Remarks

Laurence Reid Latest Holdings Summary

Laurence Reid currently owns a total of 2 stocks. Among these stocks, Laurence Reid owns 5,671 shares of Alnylam Pharmaceuticals Inc (ALNY) as of November 18, 2014, with a value of $2 Million and a weighting of 92.24%. Laurence Reid also owns 25,849 shares of Decibel Therapeutics Inc (DBTX) as of September 15, 2021, with a value of $126,919 and a weighting of 7.76%.

Latest Holdings of Laurence Reid

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ALNY Alnylam Pharmaceuticals Inc 2014-11-18 5,671 265.97 1,508,316
DBTX Decibel Therapeutics Inc 2021-09-15 25,849 4.91 126,919

Holding Weightings of Laurence Reid


Laurence Reid Form 4 Trading Tracker

According to the SEC Form 4 filings, Laurence Reid has made a total of 0 transactions in Alnylam Pharmaceuticals Inc (ALNY) over the past 5 years. The most-recent trade in Alnylam Pharmaceuticals Inc is the sale of 10,000 shares on November 18, 2014, which brought Laurence Reid around $906,700.

According to the SEC Form 4 filings, Laurence Reid has made a total of 1 transactions in Decibel Therapeutics Inc (DBTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Decibel Therapeutics Inc is the acquisition of 10,000 shares on September 15, 2021, which cost Laurence Reid around $76,400.

Insider Trading History of Laurence Reid

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Laurence Reid Trading Performance

GuruFocus tracks the stock performance after each of Laurence Reid's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Laurence Reid is -23.35%. GuruFocus also compares Laurence Reid's trading performance to market benchmark return within the same time period. The performance of stocks bought by Laurence Reid within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Laurence Reid's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Laurence Reid

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -3.56 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -4.95 LIMIT LIMIT LIMIT LIMIT LIMIT

Laurence Reid Ownership Network

Ownership Network List of Laurence Reid

No Data

Ownership Network Relation of Laurence Reid

Insider Network Chart

Laurence Reid Owned Company Details

What does Alnylam Pharmaceuticals Inc do?

Who are the key executives at Alnylam Pharmaceuticals Inc?

Laurence Reid is the SVP & Chief Business Officer of Alnylam Pharmaceuticals Inc. Other key executives at Alnylam Pharmaceuticals Inc include EVP & Chief Commercial Officer Yvonne Greenstreet , EVP & Chief Commercial Officer Tolga Tanguler , and CMO & EVP Dev & Med Affairs Pushkal Garg .

Alnylam Pharmaceuticals Inc (ALNY) Insider Trades Summary

Over the past 18 months, Laurence Reid made no insider transaction in Alnylam Pharmaceuticals Inc (ALNY). Other recent insider transactions involving Alnylam Pharmaceuticals Inc (ALNY) include a net sale of 52,531 shares made by Yvonne Greenstreet , a net sale of 10,304 shares made by Pushkal Garg , and a net sale of 5,639 shares made by Jeffrey V. Poulton .

In summary, during the past 3 months, insiders sold 57,275 shares of Alnylam Pharmaceuticals Inc (ALNY) in total and bought 0 shares, with a net sale of 57,275 shares. During the past 18 months, 249,128 shares of Alnylam Pharmaceuticals Inc (ALNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 249,128 shares.

Alnylam Pharmaceuticals Inc (ALNY)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Alnylam Pharmaceuticals Inc Insider Transactions

No Available Data

Laurence Reid Mailing Address

Above is the net worth, insider trading, and ownership report for Laurence Reid. You might contact Laurence Reid via mailing address: 300 Third Street, Cambridge Ma 02142.